Abstract
Polymorphisms in carcinogen- and drug-metabolizing enzymes may increase the risk of acute myeloid leukemia (AML) and may influence prognosis. We report that the polymorphic variant of the cytochrome P450 CYP1A1*2A, present in 11.3% of patients, is an independent unfavorable prognostic factor for failure-free and overall survival in patients with AML.Figures & Tables
Article Information
Published
2005-01-01
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
Article Usage
Online Views
396
PDF Downloads
322
No Data